Skip to main content

Day: November 13, 2024

SELLAS Life Sciences Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Pre-specified Events to Trigger Interim Analysis of Phase 3 REGAL Study in Patients with Acute Myeloid Leukemia (AML) Remains on Track for Q4 2024 – – Data from the Phase 2a Trial of SLS009 in Relapsed/Refractory AML After Venetoclax Failure to be Presented at the Upcoming American Society of Hematology (ASH) Annual Meeting in December – – GPS Granted FDA Rare Pediatric Disease Designation (RPDD) for the Treatment of Pediatric AML – NEW YORK, Nov. 13, 2024 (GLOBE NEWSWIRE) — SELLAS Life Sciences Group, Inc. (NASDAQ: SLS) (“SELLAS’’ or the “Company”), a late-stage clinical biopharmaceutical company focused on the development of novel therapies for a broad range of cancer indications, today reported financial results for the third quarter ended September 30, 2024, and provided a corporate update. “We continue to make considerable...

Continue reading

KULR Reports Record Revenue for the Third Quarter of 2024

HOUSTON, Nov. 13, 2024 (GLOBE NEWSWIRE) — KULR Technology Group, Inc. (NYSE American: KULR) (the “Company” or “KULR”), a global leader in sustainable energy management, today reported results for the third quarter ended September 30, 2024. Third Quarter 2024 Financial Results Revenues: In the third quarter that ended September 30, 2024, revenue was $3.19 million compared to $3.04 million reported in the same period last year. Cash and Accounts Receivable: As of September 30, 2024, the Company had cash and accounts receivable combined of $3.60 million. Gross Margins: Gross margin was 71% in the quarter ending September 30, 2024, compared to 44% in the same period last year. Selling, General and Administrative (SG&A) Expenses: SG&A expenses decreased to $2.74 million in the third quarter of 2024...

Continue reading

Stryve Foods, Inc. Reports Fiscal 2024 Third Quarter Results

36.4% Growth in Net Sales Year-over-YearGross Profit Up 122.1% versus Prior Year$2.9M in Gross Proceeds Raised to Support Growing Demand PLANO, Texas, Nov. 13, 2024 (GLOBE NEWSWIRE) — Stryve Foods, Inc. (“Stryve” or “the Company”) (NASDAQ: SNAX), an emerging healthy snacking platform and leader in the air-dried meat snack industry in the United States, today reports financial and operating results for the three and nine months ended September 30, 2024. The Company reported continued revenue growth, improved gross margins, and reduced operating expenses, highlighting the effectiveness of its transformation strategy. Key highlights include net sales of $5.7 million, reflecting a 36.4% increase from the third quarter of 2023, and more than doubling gross profit year over year with a gross margin of 21.7%, as compared to 13.3% in the...

Continue reading

Pharvaris Reports Third Quarter 2024 Financial Results and Highlights Recent Business Updates

Positive long-term extension data highlighting the differentiated profile of deucrictibant for the prevention and treatment of HAE attacks presented at recent medical congresses Intend to engage in clinical development of deucrictibant for the treatment of acquired angioedema due to C1-INH deficiency (AAE-C1INH) Initiation of CHAPTER-3 global pivotal Phase 3 clinical study of deucrictibant for the prophylactic treatment of HAE using once-daily extended-release tablet expected by YE2024 Operating from a strong financial position with cash and cash equivalents of €305 million as of September 30, 2024ZUG, Switzerland, Nov. 13, 2024 (GLOBE NEWSWIRE) — Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor antagonists to prevent and treat hereditary angioedema (HAE) attacks,...

Continue reading

Lulus Reports Third Quarter 2024 Results

Significant Sequential Quarterly Net Revenue Comp Improvement with Q3 Reaching Negative Low Single Digits Updated Outlook for Q4 and Fiscal Year 2024 CHICO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Lulu’s Fashion Lounge Holdings, Inc. (“Lulus” or the “Company”) (Nasdaq: LVLU) today reported financial results for the third quarter ended September 29, 2024. Crystal Landsem, CEO of Lulus, said: “Third quarter net revenue came in ahead of our outlook, driven by record growth in special occasion and bridesmaid dress categories, boosting overall dress sales and reinforcing our strength in event apparel. This gain was offset by continued softness in our casual wear business, which we are strategically reevaluating to better align with our core focus on event attire. As a result, we took a proactive approach to inventory management, leveraging...

Continue reading

Alumis Reports Third Quarter 2024 Financial Results and Highlights Recent Achievements

– Presented data at EADV supporting potential of ESK-001 as differentiated oral treatment in immune-mediated diseases through maximal TYK2 inhibition – – Continued to advance three clinical programs, including global Phase 3 ONWARD clinical trials for ESK-001 in moderate-to-severe plaque psoriasis, Phase 2b clinical trial for ESK-001 in systemic lupus erythematosus (SLE) and Phase 1 clinical study for A-005 being developed for neuroinflammatory and neurodegenerative diseases – SOUTH SAN FRANCISCO, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — Alumis Inc. (Nasdaq: ALMS), a clinical-stage biopharmaceutical company developing oral therapies using a precision approach to optimize clinical outcomes and significantly improve the lives of patients with immune-mediated diseases, today reported financial results for the third quarter ended September...

Continue reading

NextNav Inc. Reports Third Quarter 2024 Results

The Brattle Group Analysis Finds Total Quantified Value of Having a GPS Backup is $14.6 billion NextNav Continues Engineer-to-Engineer Dialogue with Appropriate Stakeholders RESTON, Va., Nov. 13, 2024 (GLOBE NEWSWIRE) — NextNav Inc. (NASDAQ: NN) a leader in next generation positioning, navigation, and timing (PNT) and 3D geolocation, today reported financial results for NextNav’s third quarter ended September 30, 2024. Mariam Sorond, NextNav CEO said, “In the third quarter, we continued efforts to advance our strategic vision and address the critical need for a terrestrial complement and backup to GPS. The NextNav team continues to hold active discussions with the appropriate stakeholders through engineer-to-engineer dialogue in support of our petition. We believe that collaborative analysis is essential to achieving an outcome...

Continue reading

ImmuCell Announces Unaudited Financial Results for the Quarter Ended September 30, 2024

PORTLAND, Maine, Nov. 13, 2024 (GLOBE NEWSWIRE) — ImmuCell Corporation (Nasdaq: ICCC) (“ImmuCell” or the “Company”), a growing animal health company that develops, manufactures and markets scientifically proven and practical products that improve the health and productivity of dairy and beef cattle, today announced its unaudited financial results for the quarter ended September 30, 2024. Q3 2024 Highlights:Product sales increased 11% over the comparable quarter in 2023. Product sales increased 51% over the comparable nine-month period in 2023. Product sales increased 46% over the previous trailing twelve-month period ended September 30, 2023.Management’s Discussion:“Our preliminary, unaudited product sales for the third quarter of 2024 were first reported on October 8, 2024,” commented Michael F. Brigham, President and CEO...

Continue reading

Espey Mfg. & Electronics Corp. reports first quarter results

SARATOGA SPRINGS, N.Y., Nov. 13, 2024 (GLOBE NEWSWIRE) — Espey Mfg. & Electronics Corp. (NYSE American: ESP) announces results for the first three months of fiscal year 2025. Net sales for the first quarter of fiscal year 2025, July 1 to September 30, 2024, were $10,443,218, compared with last year’s first quarter net sales of $8,568,214. Net income for the quarter was $1,598,317, $0.61 per diluted share, as compared to net income of $1,094,544, $0.44 per diluted share for the same quarter last year. The backlog for the Company was approximately $94.6 million at September 30, 2024, compared with last year’s backlog of approximately $87.1 million at September 30, 2023. New orders in the first three months of fiscal year 2025 were approximately $7.8 million, compared with new orders in the first three months of fiscal...

Continue reading

AEON Biopharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update

– Held biosimilar advisory meeting with FDA in Q3 2024, and aligned on next steps for a 351(k) regulatory pathway to approval for ABP-450 (prabotulinumtoxinA) as a biosimilar utilizing BOTOX® (onabotulinumtoxinA) as the reference product – – Plan to initiate comparative analytical studies anticipated in Q4 2024 subject to available resources – – 351(k) regulatory pathway offers potential to bring ABP-450 to the U.S. market under a single approval for all of BOTOX’s currently approved and future therapeutic indications – IRVINE, Calif., Nov. 13, 2024 (GLOBE NEWSWIRE) — AEON Biopharma, Inc. (“AEON” or the “Company”) (NYSE: AEON), a clinical-stage biopharmaceutical company focused on developing a botulinum toxin complex for the treatment of multiple therapeutic indications, announced financial results for the third quarter ended September...

Continue reading

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals

Before you continue, please confirm the following:

Professional advisers only

I am a professional adviser and would like to visit the GOLDEA CAPITAL for Professionals website.

Cookie Notice

We use cookies to improve your experience on our website

Information we collect about your use of Goldea Capital website

Goldea Capital website collects personal data about visitors to its website.

When someone visits our websites, we use a third party service, Google Analytics, to collect standard internet log information (such as IP address and type of browser they’re using) and details of visitor behavior patterns. We do this to allow us to keep track of the number of visitors to the various parts of the sites and understand how our website is used. We do not make any attempt to find out the identities or nature of those visiting our websites. We won’t share your information with any other organizations for marketing, market research or commercial purposes and we don’t pass on your details to other websites.

Use of cookies
Cookies are small text files that are placed on your computer or other device by websites that you visit. They are widely used to make websites work, or work more efficiently, as well as to provide information to the owners of the site.